Close Menu

More articles about Point-of-Care Testing

Researchers in Nigeria are developing a handheld diagnostic device for identifying high-risk colorectal cancer patients in low-resource environments.

The firm said that the test, a hematology-based cellular biomarker that identifies morphological changes within monocyte white blood cells, could speed diagnosis.

The microfluidic immunoassay uses spectrometry and a lateral flow method to diagnose the "very large global health problem" in about 20 minutes.

Within the diagnostics business, Abbott's core laboratory sales grew 4 percent but its other diagnostic segments were down year over year.

The company envisions creating a "vocometer … to provide disease screening and management solutions based on acoustic analysis of seconds of voice."

The PCR-based Carba assay is designed to detect and differentiate bacterial gene sequences that are associated with resistance to carbapenem antibiotics.

The biological activity sensors in development consist of nanoparticles conjugated with a peptide substrate produce fluorescence in urine associated with immunotherapy response.

ArcDia will provide Xinhua its biochemical assay components and R&D services in order to localize the Finnish firm's MariPOC testing platform in China.

Bluejay's point-of-care test is designed to measure the presence of human immunoglobulin E in a tear sample, providing results within 10 minutes.

The approval advances Chembio’s commercial agreement with Bio-Manguinhos to develop and supply rapid diagnostic tests for Zika, dengue, and chikungunya.

The firm said that it is now working toward obtaining the necessary regulatory classification to allow placement of its platelet testing devices in physician offices.

CEO Yoel Ezra said the firm plans to deploy a prototype in pilot studies next year, and is eyeing opportunities in the US, Europe, India, and the Middle East.

The spread of POC testing technology along with changes in state regulations and pharmacist education are driving an increase in pharmacist-administered testing.

The FDA cleared the firm's Coag-Sense PT2 second-generation PT/INR monitoring system for professional use in a CLIA setting and by patients at home.

The firm anticipates that it will soon launch the device as an in vitro diagnostic tool for analyzing tissue biopsies during surgeries in European hospitals.

The biomarkers — ubiquitin carboxyl terminal hydrolase-L1 and glial fibrillary acidic protein — can be detected in blood soon after a brain injury.

The firm has expansive plans, including a possible launch of 40 different types of tests. It currently plans to launch a liver function test in the US this summer.

Chembio said it will receive funding to develop a test that combines its Dual Path Platform (DPP) technology with a Perseus concussion biomarker.

Bluejay said that the collaboration will focus on the study of antigens associated with various pathogens and identifying the most immunoreactive antigen.

Ohio State researchers found in a preliminary study that spectroscopy detected fibromyalgia and differentiated the condition from similar ailments.

Pages